125 related articles for article (PubMed ID: 26585163)
1. Molecular Design, Synthesis, and Evaluation of SNIPER(ER) That Induces Proteasomal Degradation of ERα.
Okuhira K; Demizu Y; Hattori T; Ohoka N; Shibata N; Kurihara M; Naito M
Methods Mol Biol; 2016; 1366():549-560. PubMed ID: 26585163
[TBL] [Abstract][Full Text] [Related]
2. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells.
Okuhira K; Demizu Y; Hattori T; Ohoka N; Shibata N; Nishimaki-Mogami T; Okuda H; Kurihara M; Naito M
Cancer Sci; 2013 Nov; 104(11):1492-8. PubMed ID: 23992566
[TBL] [Abstract][Full Text] [Related]
3. Molecular Design, Synthesis, and Evaluation of SNIPER (ER) that Induces Targeted Protein Degradation of ERα.
Ohoka N; Yokoo H; Okuhira K; Demizu Y; Naito M
Methods Mol Biol; 2022; 2418():363-382. PubMed ID: 35119675
[TBL] [Abstract][Full Text] [Related]
4.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
5. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway.
Ohoka N; Nagai K; Hattori T; Okuhira K; Shibata N; Cho N; Naito M
Cell Death Dis; 2014 Nov; 5(11):e1513. PubMed ID: 25375378
[TBL] [Abstract][Full Text] [Related]
7. Novel flexible heteroarotinoid, SL-1-18, promotes ERα degradation to inhibit breast cancer cell growth.
Fallatah MM; Liu S; Sevigny MB; Zou H; Louie MC
Cancer Lett; 2017 Nov; 408():82-91. PubMed ID: 28844711
[TBL] [Abstract][Full Text] [Related]
8. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
9. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
10. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy.
Demizu Y; Okuhira K; Motoi H; Ohno A; Shoda T; Fukuhara K; Okuda H; Naito M; Kurihara M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1793-6. PubMed ID: 22277276
[TBL] [Abstract][Full Text] [Related]
12. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
Fan M; Park A; Nephew KP
Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
[TBL] [Abstract][Full Text] [Related]
13. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
14. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
16. SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib.
Ohoka N; Nagai K; Shibata N; Hattori T; Nara H; Cho N; Naito M
Cancer Sci; 2017 May; 108(5):1032-1041. PubMed ID: 28192613
[TBL] [Abstract][Full Text] [Related]
17. REGγ regulates ERα degradation via ubiquitin-proteasome pathway in breast cancer.
Chai F; Liang Y; Bi J; Chen L; Zhang F; Cui Y; Jiang J
Biochem Biophys Res Commun; 2015 Jan; 456(1):534-40. PubMed ID: 25490392
[TBL] [Abstract][Full Text] [Related]
18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
19. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells.
Fan M; Bigsby RM; Nephew KP
Mol Endocrinol; 2003 Mar; 17(3):356-65. PubMed ID: 12554766
[TBL] [Abstract][Full Text] [Related]
20. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
